JP2024529070A5 - - Google Patents
Info
- Publication number
- JP2024529070A5 JP2024529070A5 JP2024507174A JP2024507174A JP2024529070A5 JP 2024529070 A5 JP2024529070 A5 JP 2024529070A5 JP 2024507174 A JP2024507174 A JP 2024507174A JP 2024507174 A JP2024507174 A JP 2024507174A JP 2024529070 A5 JP2024529070 A5 JP 2024529070A5
- Authority
- JP
- Japan
- Prior art keywords
- heterocycloalkyl
- cycloalkyl
- independently
- pharmaceutically acceptable
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110919812.6 | 2021-08-11 | ||
| CN202110919812 | 2021-08-11 | ||
| CN202111188963 | 2021-10-12 | ||
| CN202111188963.5 | 2021-10-12 | ||
| CN202210918443.3 | 2022-08-01 | ||
| CN202210918443 | 2022-08-01 | ||
| PCT/CN2022/111893 WO2023016529A1 (zh) | 2021-08-11 | 2022-08-11 | 作为atr抑制剂的萘啶衍生物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024529070A JP2024529070A (ja) | 2024-08-01 |
| JP2024529070A5 true JP2024529070A5 (enExample) | 2025-08-19 |
Family
ID=85199870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024507174A Pending JP2024529070A (ja) | 2021-08-11 | 2022-08-11 | Ａｔｒ阻害剤としてのナフチリジン誘導体およびその調製方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240317741A1 (enExample) |
| EP (1) | EP4385992A4 (enExample) |
| JP (1) | JP2024529070A (enExample) |
| CN (1) | CN117642401A (enExample) |
| AU (1) | AU2022325376A1 (enExample) |
| CA (1) | CA3227336A1 (enExample) |
| TW (1) | TWI831325B (enExample) |
| WO (1) | WO2023016529A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| US10729680B2 (en) * | 2016-01-14 | 2020-08-04 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| WO2018153970A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine |
| KR20210097124A (ko) * | 2018-10-30 | 2021-08-06 | 리페어 세라퓨틱스 인크. | 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법 |
| CN116234551A (zh) * | 2020-09-27 | 2023-06-06 | 南京明德新药研发有限公司 | 一类1,7-萘啶类化合物及其应用 |
-
2022
- 2022-08-11 WO PCT/CN2022/111893 patent/WO2023016529A1/zh not_active Ceased
- 2022-08-11 US US18/578,384 patent/US20240317741A1/en active Pending
- 2022-08-11 CN CN202280050285.2A patent/CN117642401A/zh active Pending
- 2022-08-11 EP EP22855509.0A patent/EP4385992A4/en active Pending
- 2022-08-11 JP JP2024507174A patent/JP2024529070A/ja active Pending
- 2022-08-11 CA CA3227336A patent/CA3227336A1/en active Pending
- 2022-08-11 TW TW111130300A patent/TWI831325B/zh active
- 2022-08-11 AU AU2022325376A patent/AU2022325376A1/en active Pending